[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
The patient was a 56-year-old female. At the age of 35 years, she had under gone left mastectomy and axillary lymph node dissection for breast cancer. After surgery, hormonal therapy was continued for 3 years. Then, no treatment was performed. In this study, single therapy with an AI agent was started to treatbilateral supraclavicular fossa/mediastinal lymphnode metastases. After 6 months, a partial response(PR)was achieved. However, progression of the disease(PD)was noted after 1 year. Thereafter,the regimen was switched to single high-dose(120mg/day)TOR therapy. CT revealed the disappearance of the bilateral supraclavicular fossa lymphnodes and a marked reduction of the other lymphnodes. Currently, the patient is being treated, with an interval of 10 months from the start of TOR therapy.
Murata
Tomomi
T
Department of General and Gastroenterological Surgery, Ishikawa Prefectural Central Hospital.
Yoshino
Hiroshi
H
Bandou
Hiroyuki
H
Morita
Katsuya
K
Kurokawa
Masaru
M
Inaki
Noriyuki
N
Kotake
Masanori
M
Kadoya
Shinichi
S
Yamamoto
Michihiro
M
Takayanagi
Tomoyasu
T
Yamada
Tetsuji
T
D000077384:Anastrozole; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D008408:Mastectomy; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D017312:Toremifene / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D017312:Toremifene